ORIENT-31 was the first phase III study to confirm that ICI combined with antiangiogenic therapy and chemotherapy significantly improved PFS in EGFR-mutant non-squamous NSCLC patients with EGFR-TKIs treatment progress (58). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.